Your browser doesn't support javascript.
loading
Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation.
Eyre, Toby A; Barrington, Sally F; Okosun, Jessica; Abamba, Clementina; Pearce, Rachel M; Lee, Julia; Carpenter, Ben; Crawley, Charles R; Bloor, Adrian J C; Gilleece, Maria; Nicholson, Emma; Shah, Nimish; Orchard, Kim; Malladi, Ram; Townsend, William M.
Afiliación
  • Eyre TA; Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford. toby.eyre@ouh.nhs.uk.
  • Barrington SF; King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London.
  • Okosun J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London.
  • Abamba C; BSBMTCT data registry, 5th Floor Tabard House, Talbot Yard, Guy's Hospital, Great Maze Pond, London.
  • Pearce RM; BSBMTCT data registry, 5th Floor Tabard House, Talbot Yard, Guy's Hospital, Great Maze Pond, London.
  • Lee J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London.
  • Carpenter B; Department of Haematology, University College London Hospitals 235 Euston Road, London.
  • Crawley CR; Department of Haematology and Bone Marrow Transplantation, Addenbrookes Hospital, Cambridge.
  • Bloor AJC; Department of Haematology, The Christie Hospital NHS Trust, Manchester.
  • Gilleece M; Department of Haematology and Bone Marrow Transplantation, Leeds Teaching Hospitals NHS Trust, Leeds.
  • Nicholson E; Department of Haematology and Bone Marrow Transplantation, Royal Marsden Hospital, London.
  • Shah N; Department of Haematology, Norfolk and Norwich University Hospitals, Norwich.
  • Orchard K; Department of Haematology and Bone Marrow Transplantation, Southampton University Hospitals, Southampton.
  • Malladi R; Department of Haematology and Bone Marrow Transplantation, Addenbrookes Hospital, Cambridge.
  • Townsend WM; Department of Haematology, University College London Hospitals 235 Euston Road, London.
Haematologica ; 108(3): 785-796, 2023 03 01.
Article en En | MEDLINE | ID: mdl-35586966
ABSTRACT
The optimum management approach for patients with relapsed or refractory follicular lymphoma remains uncertain. Autologous stem cell transplantation (autoSCT) is considered a standard option in suitable, younger patients with relapsed follicular lymphoma. AutoSCT is associated with very durable remissions in a minority of subjects, but also with significant, well-established toxicities. Although positron emission tomography (PET) status prior to autoSCT is an established prognostic factor in diffuse large B-cell lymphoma and Hodgkin lymphoma, no data exist in follicular lymphoma. We describe survival outcomes according to pre-transplant PET status, classified by the Lugano criteria into complete metabolic remission (CMR) versus non-CMR, in 172 patients with relapsed or refractory follicular lymphoma within a national, multicenter, retrospective British Society of Blood and Marrow Transplantation and Cellular Therapy registry study. The median number of lines of therapy prior to SCT was three (range, 1-6). The median follow-up after SCT was 27 months (range, 3-70). The median progression-free survival for all patients after autoSCT was 28 months (interquartile range, 23- 36). There was no interaction between age at transplantation, sex, number of months since last relapse, Karnofsky performance status or comorbidity index and achieving CMR prior to autoSCT. Superior progression-free survival was observed in 115 (67%) patients obtaining CMR versus 57 (33%) non-CMR patients (3-year progression-free survival 50% vs. 22%, P=0.011) and by pre-SCT Deauville score (continuous variable 1-5, hazard ratio [HR]=1.32, P=0.049). PET status was independently associated with progression-free status (non-CMR HR=2.02, P=0.003), overall survival (non-CMR HR=3.08, P=0.010) and risk of relapse (non-CMR HR=1.64, P=0.046) after autoSCT by multivariable analysis. Our data suggest that pre- SCT PET status is of clear prognostic value and may help to improve the selection of patients for autoSCT.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma Folicular / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Haematologica Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma Folicular / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Haematologica Año: 2023 Tipo del documento: Article